OTCMKTS:GNHAY

Vifor Pharma Stock Forecast, Price & News

$28.36

0.00 (0.00 %)

(As of 08/2/2021 12:00 AM ET)

Add

Compare

Today's Range

$28.36

▼

$28.36

50-Day Range

$25.81

▼

$32.10

52-Week Range

$25.81

▼

$32.10

VolumeN/A

Average Volume546 shs

Market CapitalizationN/A

P/E RatioN/A

Dividend YieldN/A

BetaN/A

30 days | 90 days | 365 days | Advanced Chart

Receive GNHAY News and Ratings via Email

Sign-up to receive the latest news and ratings for Vifor Pharma and its competitors with MarketBeat's FREE daily newsletter.

About Vifor Pharma

Vifor Pharma AG is a pharmaceutical company, which engages in the research, development, production, and marketing of therapeutic products. It operates through the following geographical segments: Switzerland, Europe, USA, Rest of World, and Group. The firm offers products for iron deficiency, nephrology, and cardio-renal therapies. The company was founded in 1927 and is headquartered in St. Gallen, Switzerland.

Vifor Pharma (OTCMKTS:GNHAY) Trading 9.7% Higher
July 22, 2021 | americanbankingnews.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Drug Manufacturers—Specialty & Generic
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:GNHAY
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.viforpharma.com
Phone(158) 851-8000
Employees147,000
Year FoundedN/A

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Outstanding SharesN/A
Market CapN/A
Next Earnings DateN/A
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

0.45 out of 5 stars

Medical Sector

1900th out of 2,226 stocks

Drug Manufacturers—Specialty & Generic Industry

52nd out of 88 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Vifor Pharma.

2.3 Community Rank

Outperform Votes
Vifor Pharma has received 1 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Vifor Pharma has received 2 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Vifor Pharma has received 66.67% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Vifor Pharma and other stocks. Vote “Outperform” if you believe GNHAY will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GNHAY will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Vifor Pharma does not currently pay a dividend.
Dividend Growth
Vifor Pharma does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Vifor Pharma insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

Vifor Pharma (OTCMKTS:GNHAY) Frequently Asked Questions

Is Vifor Pharma a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vifor Pharma in the last year. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Vifor Pharma stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GNHAY, but not buy additional shares or sell existing shares.
View analyst ratings for Vifor Pharma or view top-rated stocks.

What stocks does MarketBeat like better than Vifor Pharma?

Wall Street analysts have given Vifor Pharma a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Vifor Pharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are Vifor Pharma's key executives?

Vifor Pharma's management team includes the following people:

Stefan Schulze, President, Chief Executive & Operating Officer
Colin Bond, Chief Financial Officer
Klaus Henning Jensen, Chief Medical Officer
Gregory Oakes, Executive Vice President & President-North America
Michael Puri, Chief Human Resources Officer & Senior VP

Who are some of Vifor Pharma's key competitors?

Some companies that are related to Vifor Pharma include (CSI) (CSI), 1933 Industries (TGIFF), 4Front Ventures (FFNTF), AB Science (ABSCF), Abattis Bioceuticals (ATT), Acreage (ACRHF), Acreage (ACRDF), AFT Pharmaceuticals (AFP), Agraflora Organics International (AGRA), AgraFlora Organics International (AGFAF), Aleafia Health (ALEAF), American Green (ERBB), Ascend Wellness (AWWH), Australian Primary Hemp (APH) and Ayr Wellness (AYRWF).
View all of GNHAY's competitors.

What is Vifor Pharma's stock symbol?

Vifor Pharma trades on the OTCMKTS under the ticker symbol "GNHAY."

How do I buy shares of Vifor Pharma?

Shares of GNHAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vifor Pharma's stock price today?

One share of GNHAY stock can currently be purchased for approximately $28.36.

How many employees does Vifor Pharma have?

Vifor Pharma employs 147,000 workers across the globe.

What is Vifor Pharma's official website?

The official website for Vifor Pharma is www.viforpharma.com.

How can I contact Vifor Pharma?

The company can be reached via phone at (158) 851-8000.

This page was last updated on 8/3/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Vifor Pharma Stock Forecast, Price & News

About Vifor Pharma

Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

MarketRank™

Overall MarketRank™

0.0 Analyst's Opinion

Consensus Rating

2.3 Community Rank

Outperform Votes

Underperform Votes

Community Sentiment